Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRX246 in Aggressive Participants With Fragile X Syndrome
NCT07328529Phase 2Not yet recruiting
- Sponsor
- Azevan Pharmaceuticals
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SRX246 in Fragile X syndrome (FXS), sponsored by Azevan Pharmaceuticals. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
SRX246
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT07328529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328529.